On 25 October 2022 leading researchers and executives from some of the world’s pioneering drug and pharmaceutical companies came together at a Financial Times Live Webinar event to discuss “The Power of Clinical Trial Tokenization”.
On 1 December 2022, both the National Budget Law No. 27,701 and the enactment Decree 799/2022 were published in the Official Gazette. The Law introduces important changes regarding the maximum applicable sanctions applicable in consumer defense matters, as well as regarding punitive damages.
On 29 November 2022, the Plenary of the Federal Senate approved the final text of Bill of Law No. 4,401/2021 in which the Deputy Expedito Netto is the rapporteur. Currently, PL No. 4.401/2021 is in the final processing stage, which consists of the Brazilian president’s sanction. In summary, PL No. 4,401/2021 aims to regulate service providers of the “virtual assets” market (which includes the denominated “cryptoassets”), as well as adapt the wording of the Brazilian Penal Code, the Brazilian Law on Crimes against the National Financial System and the Brazilian Law on Crimes of Money Laundering or Concealment of Assets, Rights and Values.
In its decision of 12 September 2022, the Swiss Federal Administrative Court confirmed that interpretive software that uses indicators such as calendar days and body temperature to monitor fertile and infertile phases of a menstrual cycle to achieve natural conception or prevent undesired pregnancy, qualifies as a medical device. This means that such software is subject to a conformity certification procedure with a notified body.
On 1 December 2022, Switzerland’s new Human Genetic Testing Act will enter into force.
The new HGTA provides a comprehensive legal framework for all types of genetic testing (including direct-to-consumer genetic testing and lifestyle genetic testing) and implements stronger measures to protect privacy rights, prevent abuse of genetic data and ensure the quality of genetic tests and the interpretation of the results.
As part of the comprehensive revision of the HGTA, the Human Genetic Testing Ordinance and the Ordinance on the creation of DNA profiles for civil and administrative purposes have been amended accordingly.
As we embark on the journey towards net zero, financial institutions aspire to increase their understanding of Sustainability-related commercial and regulatory developments. We are inviting you to our upcoming webinar on 12 December 2022, which aims to cover global trends and highlight perspectives from Latin America.
On 30 September 2022, the State Bank of Vietnam officially issued Circular No. 12/2022/TT-NHNN providing instructions on foreign exchange administration regarding offshore borrowing and offshore debt repayment of enterprises (“Circular 12”). Circular 12 came into effect on 15 November 2022, replacing Circular No. 03/2016/TT-NHNN and its amending circulars.
On 24 November 2022, the Health Sciences Authority published its Regulatory Guidelines for Laboratory Developed Tests. The new guidelines will come into effect from 1 March 2023. The HSA first published a draft version of the Regulatory Guidelines for LDTs on 12 July 2022. It invited stakeholders to provide feedback on the document, and held a public consultation period from 12 July 2022 to 12 August 2022.
On 14 November 2022, the Health Sciences Authority issued an alert on five products that it found to contain potent medicinal ingredients and informed the public not to purchase such products. Two of the products were obtained from Malaysia through the consumers’ friends and relatives; while the other three were available on local e-commerce platforms. The HSA has worked with the platforms to remove the affected listings.
Following the judgment of the Court of Justice of the European Union of 22 November 2022, access to the Luxembourg register of beneficial owners website via the internet has been temporarily suspended. This judgment, taken on a preliminary ruling from the Luxembourg District Court in a dispute between the beneficial owners of an entity registered in Luxembourg and the Luxembourg Business Register, underlines that access without distinction of user quality, although imposed by the text of Directive (EU) 2018/843 of the European Parliament and of the Council of 30 May 2018 amending Directive (EU) 2015/849 on the prevention of the use of the financial system for the purposes of money laundering or terrorist financing transposed into Luxembourg law, is contrary, in particular, to Articles 7 and 8 of the Charter of Fundamental Rights of the European Union.